PROVENZANO, CLAUDIA
 Distribuzione geografica
Continente #
NA - Nord America 118
AS - Asia 57
EU - Europa 34
OC - Oceania 1
Totale 210
Nazione #
US - Stati Uniti d'America 118
SG - Singapore 48
IT - Italia 23
KR - Corea 5
DK - Danimarca 2
FI - Finlandia 2
GB - Regno Unito 2
JP - Giappone 2
AT - Austria 1
AU - Australia 1
BE - Belgio 1
DE - Germania 1
HK - Hong Kong 1
IE - Irlanda 1
IN - India 1
NL - Olanda 1
Totale 210
Città #
Santa Clara 104
Singapore 34
Rome 20
Seoul 5
Columbia 3
Aarhus 2
Helsinki 2
Milan 2
Amsterdam 1
Ashburn 1
Brussels 1
Dublin 1
Falkenstein 1
Hong Kong 1
Hull 1
London 1
Springfield 1
Vienna 1
Yass 1
Totale 183
Nome #
Gene Therapy Strategies For Myotonic Dystrophy Type 1 21
High-throughput analysis of the RNAinduced silencing complex in myotonic dystrophy type 1 patients identifies the dysregulation of miR-29c and its target ASB2 21
CRISPR/Cas9-MediatedDeletion ofCTGExpansions Recovers Normal Phenotype in Myogenic Cells Derived from Myotonic Dystrophy 1 Patients 16
Muscle-specific gene editing improves molecular and phenotypic defects in a mouse model of Myotonic Dystrophy type 1 15
GENE EDITING IN MYOTONIC DYSTROPHY TYPE 1: ASSESSMENT OF EFFICIENCY, SAFETY AND THERAPEUTIC EFFECT OF CTG-REPEAT DELETION IN A MOUSE MODEL OF DISEASE 12
Functional characterization of two novel mutations in TTF-1/NKX2.1 homeodomain in patients with benign hereditary chorea 12
MiR-21 is an Ngf-modulated MicroRNA That supports Ngf signaling and regulates neuronal degeneration in PC12 cells 11
Application of CRISPR/Cas9 strategy for gene therapy of Myotonic Dystrophy type 1 10
Circular RNA role in Myotonic Dystrophy type 1 10
Retinoblastoma protein acts as Pax 8 transcriptional coactivator. 9
Study of pathogenetic mechanisms and development of new therapeutic strategies for Myotonic Dystrophy type 1 8
Functional characterization of a novel mutations in TITF-1 in a patient with Benign Hereditary Chorea. 8
Design of novel small molecule base-pair recognizers of toxic CUG RNA transcripts characteristics of DM1 8
Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing 8
Does the term 'trophic' actually mean anti-amyloidogenic? The case of NGF 7
GENE EDITING IN MYOTONIC DYSTROPHY TYPE 1: ASSESSMENT OF EFFICIENCY, SAFETY AND THERAPEUTIC EFFECT OF CTG-REPEAT DELETION IN A MOUSE MODEL OF DISEASE 7
Large scale analysis of transcription factor TTF-1/NKX2.1 target genes in GnRH secreting cell line GT1-7 7
BEHAVIOURAL ABNORMALITIES IN DMSXL MICE, A MODEL OF MYOTONIC DYSTROPHY TYPE 1 7
Eps8, a tyrosine kinase substrate, is recruited to the cell cortex and dynamic F-actin upon cytoskeleton remodeling. 6
Inducible CRISPR/Cas9 strategy mediates efficient gene editing of trinucleotide repeat expansion in DMPK locus 6
v-Src inhibits myogenic differentiation by interfering with the regulatory network of muscle-specific transcriptional activators at multiple levels 6
MicroRNA-222 regulates muscle alternative splicing through Rbm24 during differentiation of skeletal muscle cells 6
Maintenance of the differentiated state in skeletal muscle: activation of v-Src disrupts sarcomeres in quail myotubes 5
Time-controlled and muscle-specific CRISPR/Cas9 mediated deletion of CTG-repeat expansion in the DMPK gene 5
Regulation of the tyrosine kinase substrate Eps8 expression by growth factors, v-Src and terminal differentiation. 5
CRISPR/Cas9-mediated genomic deletions of trinucleotide repeats in Myotonic Dystrophy type 1: a new tool for gene therapy? 4
Glucocorticoids modulate transformation by v-Src in a cell-specific manner. 4
Transformation of NIH3T3 cells by Rous sarcoma virus occurs with high efficiency in the absence of proviral rearrangements or amplification. 4
A dominant-negative peroxisome proliferator-activated receptor gamma (PPAR gamma) mutant is a constitutive repressor and inhibits PPAR gamma-mediated adipogenesis 4
Totale 252
Categoria #
all - tutte 995
article - articoli 616
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.611


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202436 0 0 0 0 0 0 0 0 0 0 9 27
2024/2025216 8 3 46 19 103 36 1 0 0 0 0 0
Totale 252